Monopar Therapeutics Inc. (MNPR), a clinical-stage biopharmaceutical company, Thursday, announced that it has dosed the first patient in a phase Ia study evaluating therapeutic radiopharmaceutical MNPR-101-Lu in patients with solid tumor cancers.
MNPR-101-Lu combines MNPR-101, Monopar's antibody that selectively targets the urokinase plasminogen activator receptor, with the therapeutic radioisotope lutetium-177.
Urokinase plasminogen activator receptor is a protein that plays a role in tumor growth and spread and is found in many cancers, such as pancreatic, ovarian, triple-negative breast, and colorectal cancers.
The first patient dosed with MNPR-101-Lu has metastatic pancreatic cancer. Imaging using MNPR-101-Zr revealed the presence of uPAR expression in the patient.
MNPR-101-Zr for imaging is also under phase I trial and enrollment is underway.
MNPR closed Thursday's trading at $21.00, down 14.84%. In after-hours trading, the stock was up over 13% at $23.80.
For comments and feedback contact: editorial@rttnews.com
Business News
April 24, 2026 15:15 ET Economics news flow was relatively light this week even as the conflict in the Middle East continued, raising concerns for policymakers. In the U.S., spending data, initial jobless claims and pending home sales were the highlights. Business confidence in the biggest euro area economy was in focus in Europe. Inflation data from Japan gained attention in Asia.